What does qarziba — financial royalty assets, allowance mean?

Represents the contra-asset account used to reduce the gross carrying value of royalty-based assets due to expected credit losses or potential impairment. This metric is critical for assessing the risk profile and recoverability of the company's investment in the specific product.

Ligand Pharmaceuticals LGND Qarziba — Financial Royalty Assets, Allowance

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

NOVRoyalty — Contract With Customer Receivable After Allowance For Credit Loss

$43M+231%

WECValuation Allowances And Reserves Charged To Cost And Expense

$35.7M+36.1%

NOVRoyalty — Contract With Customer Receivable Before Allowance For Credit Loss

$137M+3.0%

JXNValuation Allowances And Reserves Charged To Cost And Expense

$11M-57.7%

TRTXAllowance for credit losses

$74.03M+14.4%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's qarziba — financial royalty assets, allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's qarziba — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported qarziba — financial royalty assets, allowance of $480K in Q1 2026.
What does qarziba — financial royalty assets, allowance mean?: Represents the contra-asset account used to reduce the gross carrying value of royalty-based assets due to expected credit losses or potential impairment. This metric is critical for assessing the risk profile and recoverability of the company's investment in the specific product.